Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin + Rosuvastatin fixed-dose combination vs monotherapies in type 2 diabetes and dyslipidemia
KCT0001405Phase 3Recruiting
- Sponsor
- LG Chem
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemigliptin, rosuvastatin in type 2 diabetes mellitus (T2DM), dyslipidemia, sponsored by LG Chem. Started May 2014; status: recruiting.
02
Drugs
gemigliptinrosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on KCT0001405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001405.